Is ANPCY or EQR a better dividend investment in 2026?

ANPCY currently yields 2985.07% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: ANPCY offers higher current income.

What is the dividend yield difference between ANPCY and EQR?

ANPCY has a forward dividend yield of 2985.07% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 2979.20 percentage points.

Home › Compare › ANPCY vs EQR

ANPCY vs EQR: Dividend Comparison 2026

ANPCY yields 2985.07% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ANPCY wins by $433539968075.07M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ANPCY

● Live price

2985.07%

Share price

$0.07

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$433539968075.12M

Annual income

$406,736,225,519,142,500.00

Full ANPCY calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — ANPCY vs EQR

📍 ANPCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ANPCY	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ANPCY + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ANPCY pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANPCY

Annual income on $10K today (after 15% tax)

$253,731.34/yr

After 10yr DRIP, annual income (after tax)

$345,725,791,691,271,200.00/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, ANPCY beats the other by $345,725,791,691,266,500.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANPCY + EQR for your $10,000?

ANPCY: 50%EQR: 50%

100% EQR50/50100% ANPCY

Portfolio after 10yr

$216769984037.58M

Annual income

$203,368,112,759,574,000.00/yr

Blended yield

93.82%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ANPCY

No analyst data

Altman Z

-11.9

Piotroski

2/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANPCY buys

EQR buys

No recent congressional trades found for ANPCY or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricANPCYEQR

Forward yield	2985.07% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$433539968075.12M ✓	$47.8K
Annual income after 10y	$406,736,225,519,142,500.00 ✓	$5,475.61
Total dividends collected	$431686299125.80M ✓	$23.0K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: ANPCY vs EQR ($10,000, DRIP)

Year	ANPCY Portfolio	ANPCY Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$309,207	$298,507.46	$11,380	$679.82	+$297.8K → ANPCY
2	$8,957,089	$8,626,236.93	$13,014	$837.25	+$8.94M → ANPCY
3	$243,120,454	$233,536,368.64	$14,961	$1,036.20	+$243.11M → ANPCY
4	$6,184,279,490	$5,924,140,604.30	$17,297	$1,289.22	+$6184.26M → ANPCY
5	$147,451,722,719	$140,834,543,664.57	$20,121	$1,613.15	+$147451.70M → ANPCY
6	$3,296,013,356,428	$3,138,240,013,119.13	$23,561	$2,030.84	+$3296013.33M → ANPCY
7	$69,087,118,460,072	$65,560,384,168,694.19	$27,783	$2,573.54	+$69087118.43M → ANPCY
8	$1,358,221,282,082,432	$1,284,298,065,330,154.50	$33,013	$3,284.39	+$1358221282.05M → ANPCY
9	$25,050,226,687,827,436	$23,596,929,915,999,230.00	$39,547	$4,223.51	+$25050226687.79M → ANPCY
10	$433,539,968,075,117,900	$406,736,225,519,142,500.00	$47,791	$5,475.61	+$433539968075.07M → ANPCY

ANPCY vs EQR: Complete Analysis 2026

ANPCY — Stock

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Full ANPCY Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this ANPCY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANPCY vs SCHD ANPCY vs JEPI ANPCY vs O ANPCY vs KO ANPCY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.